Epizyme, Inc.

Hello and welcome to the EpiVine fourth quarter and full year 2021 Financial Results Conference call. At this time, all participants are in a listen-only mode. Following the prepared remarks, there will be a question and answer session. Please be advised that today's call is being recorded. I would now turn the call over to Kristen Hilton, Investor Relations. You may begin.

Thank you, operator. This morning, Epizyme issued a press release providing a business update in addition to fourth quarter and full year 2021 financial results. That press release can be found in the investor section of the company's website at epizyme.com. On the call today are Grant Bogle, President and CEO of Epizyme, and Dr. Shefali Agarwal, Executive Vice President and Chief Medical and Development Officer. Joe Bollier, Vice President and Corporate Controller and Treasurer, will join us for the Q&A. As a reminder, today's discussion will include forward-looking statements related to Epizyme's current plans and expectations, which are subject to certain risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factors section of our most recent forms 10Q, 10K, and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date and we undertake no obligation to publicly update these statements. At this time, I would like to turn the call over to Grant Vogel.

Grant? Thank you, Kristen, and good morning, everyone. It's great to be here with you and to provide an update on our fourth quarter and full year 2021 results. On today's call, I will review company results, including commercial performance of TASVERIC, and provide additional business commentary insights on our cash position, and updated guidance for 2022. Shefali will speak to our clinical development progress for Tazimetastat and EZM0414, our investigational CETD2 inhibitor, in more detail. Following our remarks, we will open the line for questions. During the fourth quarter, we reported TASVERIC net product revenue of $11.6 million, including 4.2 million related to the sale of TASVARIC commercial product for third party pharmaceutical company use in clinical trial. TASVARIC commercial net sales for the fourth quarter of 2021 were 7.4 million, representing an increase of approximately 42% when compared with the third quarter of 2021. For the full year, ended December 31st, 2021, We reported TASVERIC net product revenue of $30.9 million, including $7.4 million related to the sales of TASVERIC commercial product for the third-party pharmaceutical company used in clinical trial. TASVERIC commercial net sales for the full year 2021 were $23.5 million. Free goods from our patient assistance program represented approximately 29% of total end-user demand. for the fourth quarter of 2021 and approximately 24% for the full year of 2021. Total end-user demand in the fourth quarter increased approximately 14% over third quarter 2021 levels, driven primarily by increased follicular lymphoma patient sales. We continue to make progress on our commercial efforts to drive prescription growth for TASVIRIC as a monotherapy, as well as advancing our combination clinical studies, which we believe have the potential to significantly expand the value and reach of TASVERIC among physicians and patients as the data matures. As we announced in our press release this morning, we continue to make necessary operational changes to reduce our expenses and extend our cash runway, all while strategically deploying our resources to areas we believe to be the highest impact for the company and its stakeholders. We've implemented a plan that reduces our workforce by approximately 12%, along with external spending. As part of this effort, we have also reprioritized our pipeline, including discontinue enrollment in select studies, Symphony 2 and EZH 1301. As Shefali will review in detail, we continue to study tazometastat in combination with numerous other therapies for both hematological and solid tumor cancers through our ongoing company-sponsored studies and investigator-initiated studies. I want to recognize the contribution of the EPIZON employees that are being impacted today and to thank them for all their efforts to advance our company's mission and vision. Their transition from the company is being handled appropriately to ensure that it is as smooth as possible. For those epizymers who remain with the company, I also wish to thank them for their commitment and support as we continue to focus and streamline the organization for the benefit of all stakeholders and the future of our company. These initiatives, along with the organizational and operational changes implemented when I joined as CEO last August, are designed to advance our vision of transforming the lives of patients living with cancer and helping establish TASVARIC as a foundational therapy in FL and other cancers. Looking ahead to 2022, we plan to continue to educate providers and to align systems of care to support the growth of TASVARIC monotherapy while further advancing key clinical trial programs. We are pleased with the progress we are making in our development program including the global initiation of the Phase III portion of our Symphony I study, the near-complete enrollment in the Lysa study, and the progress we are making in our Phase II prostate cancer study, CHELA I. We look forward to providing updates on these important programs, as well as other activities throughout the year. At this time, I'd now like to turn the call over to Shefali, who will speak to our clinical development progress. Shefali?